Inhibikase Therapeutics Files 8-K for 'Other Events'

TL;DR

**IKT filed an 8-K for 'Other Events' on Feb 7, signaling potential undisclosed news.**

AI Summary

Inhibikase Therapeutics, Inc. filed an 8-K on February 7, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates that the company is providing updates on its operations, potentially including new developments or disclosures that don't fit into other specific 8-K categories. For investors, this matters because 'Other Events' can sometimes signal significant, yet unclassified, corporate actions or information that could influence the stock's future performance, even if the specific details aren't immediately apparent in the summary. The company's stock, IKT, is registered on The Nasdaq Stock Market LLC.

Why It Matters

This filing signals that Inhibikase Therapeutics, Inc. is disclosing information deemed important enough for an 8-K, which could impact investor perception and stock value, even if the specific details are not yet public.

Risk Assessment

Risk Level: medium — The 'Other Events' category in an 8-K can sometimes hide significant, unclassified news, creating uncertainty for investors.

Analyst Insight

Investors should monitor Inhibikase Therapeutics, Inc.'s news releases and future SEC filings closely for specific details on the 'Other Events' mentioned, as this category can precede significant corporate developments.

Key Numbers

• 001-39676 — Commission File Number (Identifies the company's registration with the SEC.)
• 2024-02-07 — Date of Report (Indicates when the earliest event reported in the filing occurred.)
• 16 — PUBLIC DOCUMENT COUNT (Number of documents included in the filing.)

Key Players & Entities

• Inhibikase Therapeutics, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — exchange where IKT common stock is registered
• 001-39676 (dollar_amount) — Commission File Number
• February 7, 2024 (date) — Date of earliest event reported and filing date
• IKT (company) — trading symbol for Inhibikase Therapeutics, Inc.

Forward-Looking Statements

• The company will release more specific details regarding the 'Other Events' in a subsequent filing or press release. (Inhibikase Therapeutics, Inc.) — medium confidence, target: 2024-03-07

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark

Filing Documents

• d678628d8k.htm (8-K) — 26KB
• d678628dex991.htm (EX-99.1) — 15KB
• g678628g0207083653209.jpg (GRAPHIC) — 3KB
• 0001193125-24-025941.txt ( ) — 176KB
• ikt-20240207.xsd (EX-101.SCH) — 3KB
• ikt-20240207_lab.xml (EX-101.LAB) — 18KB
• ikt-20240207_pre.xml (EX-101.PRE) — 11KB
• d678628d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause the Company's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to enroll and complete the 201 Trial evaluating risvodetinib in untreated Parkinson's disease, our ability to successfully apply for and obtain FDA approval for IkT-001Pro in blood cancers and whether the FDA's signed meeting minutes differ from written pre-meeting comments or oral discussion that occurred during our pre-NDA meeting for IkT-001Pro. Additional factors include our ability to successfully conduct pre-clinical and clinical studies, and whether results of our animal studies translate to a clinical benefit in humans, as well as our need for additional financing and other such factors that are discussed in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this report speaks only as of the date of this report. The Company undertakes no obligation to publicly update or revise any forward-looking

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Number Description 99.1 Press Release dated February 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 7, 2024 INHIBIKASE THERAPEUTICS, INC. By: /S/ MILTON H. WERNER Milton H. Werner, Ph.D. President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR